Detalhe da pesquisa
1.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259589
2.
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.
Clin Cancer Res
; 28(18): 3958-3964, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35852793